Improved glycemic control for Prediabetes and/or Diabetes Type II Using Docosahexaenoic Acid

摘要

Disclosed is a use of docosahexaenoic acid (DHA) for the manufacture of a medicament for improving glucose control as measured by glycosylated hemoglobin (HbA1c) in blood wherein the medicament is adapted for administration on a periodic basis in an amount sufficient to reduce glycosylation levels of circulating hemoglobin in the patient, and wherein the medicament may be adapted for administration substantially contemporaneously with a second pharmaceutical agent preferably an antidiabetic agent.